



ASX Appendix 4C for the quarter ended September 30, 2014

For Immediate Release:

October 31, 2014

Sydney, Australia – October 31, 2014 – Simavita Limited (ASX: SVA; TSX-V: SV) (“Simavita” or the “Company”) is pleased to release its ASX Appendix 4C for the quarter ended September 30, 2014.

Cash receipts for the quarter were \$90,223. However, as the Appendix is a cash flow report, this figure does not include any revenue from US distributor Medline’s first major order which the Company expects should be reflected in the Appendix 4C for the December quarter. Assuming that these revenues are received during that quarter, the Company anticipates that the revenues generated for the first half of the 2015 financial year will exceed the revenues received during the entire previous financial year ended June 30, 2014.

As a result of a capital raising that was concluded in July 2014, the Company’s consolidated cash and cash equivalents increased during the quarter by \$784,483 such that the cash balance as at September 30, 2014 stood at \$7,633,150.

Net cash out flows from operations for the quarter were \$2,541,350. Importantly, however, trade creditors as at the beginning of the quarter under review (June 30, 2014) were \$1,022,823 while at September 30, 2014 they stood at \$512,343. Typically, year-end creditors are higher than normal as they include a number of year-end accruals and, in this case, certain significant one-off amounts relating to the Company’s previous capital raising that was completed during the September quarter.

Effectively, therefore, cash of \$510,480 (being the difference between the two creditors figures) was spent during the quarter under review paying off creditors from a prior period (i.e. pre June 30). If this reduction is applied to the net cash out flows from operations per the attached Appendix 4C of \$2,541,350, then the adjusted net cash outflows from operations for the quarter would fall to \$2,030,870.

For further information, please visit our website (www.simavita.com) or contact the persons named below.

Company	Media and Investor Relations
Philippa Lewis, Chief Executive Officer T: +61 2 8405 6381	Buchan Consulting Annabel Murphy E: amurphy@buchanwe.com.au T: +61 2 9237 2800
Tom Howitt, CFO and Company Secretary T: +61 2 8405 6391	

About Simavita

Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence-based incontinence management care plans to the residential aged care market.

About SIM™

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual. For more information on Simavita or SIM™, please visit www.simavita.com.

The TSX Venture Exchange has in no way passed upon the merits of the transactions set out herein and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking Information

This document may contain “forward-looking information” within the meaning of Canadian securities laws (“**forward-looking information**”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

SIMAVITA LIMITED

ARBN

165 831 309

Quarter ended ("current quarter")

30 SEPTEMBER 2014

Consolidated statement of cash flows

	Current quarter (September 2014) A\$	Year to date (three months) A\$
Cash flows related to operating activities		
1.1 Receipts from customers	90,223	90,223
1.2 Payments for		
(a) staff costs	(1,214,902)	(1,214,902)
(b) advertising and marketing	(234,773)	(234,773)
(c) research and development	(245,487)	(245,487)
(d) operating lease payments	(93,965)	(93,965)
(e) other working capital	(889,430)	(889,430)
(f) transaction expenses	-	-
1.3 Dividends received	-	-
1.4 Interest and items of a similar nature received	46,984	46,984
1.5 Interest and other costs of finance paid	-	-
1.6 R&D tax credit	-	-
1.7 Grant and other income	-	-
Net operating cash flows	(2,541,350)	(2,541,350)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Consolidated statement of cash flows (cont.)

	Current quarter (September 2014) A\$	Year to date (three months) A\$
1.8 Net operating cash flows (carried forward)	(2,541,350)	(2,541,350)
Cash flows related to investing activities		
1.9 Payment for the acquisition of:		
a) businesses (item 5)	-	-
b) equity investments	-	-
c) intellectual property	-	-
d) physical non-current assets	(81,490)	(81,490)
e) other non-current assets	-	-
1.10 Proceeds from the disposal of:		
a) businesses (item 5)	-	-
b) equity investments	-	-
c) intellectual property	-	-
d) physical non-current assets	-	-
e) joint venture interest	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities (refer note below)	-	-
1.13 Other (cash received on reverse takeover)	-	-
Net investing cash flows	(81,490)	(81,490)
1.14 Total operating and investing cash flows	(2,622,840)	(2,622,840)
Cash flows related to financing activities		
1.15 Proceeds from the issue of shares	3,633,496	3,633,496
1.16 Equity transaction costs	(226,173)	(226,173)
1.17 Net repayment of borrowings	-	-
1.18 Advances to third parties	-	-
1.19 Dividends paid	-	-
1.20 Repayment of finance lease principal	-	-
Net financing cash flows	3,407,323	3,407,323
Net increase / (decrease) in cash held	784,483	784,483
1.21 Cash at beginning of quarter / year to date	6,844,197	6,844,197
1.22 Exchange rate adjustments	4,470	4,470
1.23 Cash at end of quarter	7,633,150	7,633,150

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter \$A
1.24	Aggregate amount of payments to the parties included in item 1.2	207,835
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

The amount included at Item 1.24 includes amounts paid to Directors during the quarter in respect of fees and superannuation totalling \$42,835, together with a one-off fee of \$165,000 paid in respect of the Company's capital raising. The amount included at Item 1.24 does not include amounts paid to the Chief Executive Officer in her capacity as an Executive of the Company.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

None during the quarter under review

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

None during the quarter under review

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A	Amount used \$A
3.1	Loan facilities	-	-
3.2	Credit standby arrangements Hire purchase facility	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows:

	Current quarter (September 2014) \$A	Previous quarter (June 2014) \$A
4.1 Cash on hand and at bank	1,633,150	3,291,355
4.2 Term deposits	6,000,000	3,552,842
4.3 Bank overdraft	-	-
4.4 Commercial Bills of Exchange	-	-
Total cash at end of quarter (item 1.23)	7,633,150	6,844,197

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Not applicable	Not applicable
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Date: **31 October 2014**
Chief Executive Officer

Print name: **Philippa M. Lewis**

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.